convent
drug
therapi
human
virus
mainli
target
viral
enzym
tabl
repertoir
druggabl
viral
protein
correspond
small
molecul
extrem
limit
major
drawback
use
directact
drug
emerg
resist
limit
antivir
drug
discoveri
begin
explor
possibl
develop
hostori
molecul
act
cellular
function
essenti
virus
replic
inde
virus
oblig
intracellular
parasit
reli
cellular
function
replic
evolv
varieti
strategi
manipul
cellular
machineri
benefit
well
counteract
even
use
host
immun
defens
vast
major
cellular
function
support
interact
protein
manipul
cellular
process
virus
mainli
result
physic
interact
viral
host
protein
therefor
virushost
vh
interactom
interpret
context
host
interactom
allow
identif
network
cellular
protein
associ
function
essenti
viru
lifecycl
protein
consid
new
antivir
target
could
well
function
manipul
new
small
molecul
repurpos
drug
food
drug
administr
fda
approv
experiment
molecul
rescu
drug
abandon
pharmaceut
pipelin
vh
proteinprotein
interact
ppi
explor
lowscal
experi
focus
particular
viral
protein
specif
biolog
process
recent
applic
highthroughput
screen
ht
method
establish
vh
interactom
greatli
enrich
landscap
vh
ppi
also
yield
explos
candid
drug
target
furthermor
substanti
effort
made
integr
low
highthroughput
data
variou
databas
tabl
favor
transit
reductionist
integr
approach
understand
viral
infect
altogeth
wealth
vh
ppi
data
alreadi
provid
access
nearli
complet
interactom
sever
virus
public
health
concern
includ
influenza
viru
hepat
c
viru
hcv
dengu
viru
integr
inform
knowledg
uninfect
human
protein
network
highlight
key
topolog
function
featur
infect
network
highthroughput
approach
also
allow
compar
analys
virul
factor
versu
factor
oncogen
versu
nononcogen
factor
differenti
target
crucial
intracellular
pathway
one
success
fdaapprov
hosttarget
antivir
drug
maraviroc
chemokin
receptor
antagonist
treatment
hiv
infect
tabl
antivir
design
target
viral
receptor
challeng
promis
strategi
use
preexist
small
molecul
drug
intracellular
interactor
viral
protein
initi
design
treat
diseas
consid
exponenti
grow
number
candid
cellular
target
interactom
studi
drug
reposit
becom
potenti
effici
way
increas
therapeut
antivir
arsen
review
discuss
recent
advanc
approach
highthroughput
vh
ppi
screen
implic
recent
find
understand
landscap
vh
ppi
describ
main
insight
basic
research
well
potenti
antivir
drug
discoveri
final
featur
exampl
promis
success
antivir
molecul
target
host
protein
sinc
first
descript
vh
protein
interact
late
associ
methodolog
adapt
largescal
studi
yeast
twohybrid
coaffin
purif
remain
frequent
use
technolog
protein
array
proteincomplement
assay
emerg
promis
approach
highthroughput
data
product
univers
accept
definit
chosen
review
technolog
gener
vh
ppi
use
definit
report
refer
ht
vh
ppi
sinc
figur
sinc
pioneer
descript
approach
field
song
variou
technolog
improv
among
method
choic
construct
vh
interactom
figur
first
two
unbias
genomewid
vh
ppi
screen
use
technolog
perform
epsteinbarr
viru
hcv
studi
reli
initi
construct
viral
orfeom
compris
clone
open
read
frame
orf
encod
complet
set
viral
protein
led
identif
respect
vh
ppi
technolog
use
highthroughput
screen
sinc
found
studi
viral
genomewid
interactom
explor
focus
subset
viral
protein
figur
construct
viral
human
orfeom
collect
implement
versatil
recombin
clone
system
gateway
life
technolog
gaithersburg
md
usa
essenti
tool
allow
approach
becom
particularli
power
exampl
shapira
colleagu
test
interact
influenza
viru
protein
human
protein
avail
human
orfeom
versatil
gateway
system
allow
easi
transfer
cdna
compat
express
system
interact
function
studi
viralorfeom
databas
construct
provid
scientif
commun
integr
set
bioinformat
tool
enabl
potenti
captur
viral
orf
gateway
recombin
clone
system
make
avail
collect
viral
cdna
gatewaycompat
plasmid
nevertheless
interact
discov
use
screen
must
confirm
secondari
method
coaffin
purif
reduc
risk
falseposit
interact
increas
confid
dataset
usual
expect
reach
problem
falseneg
interact
difficult
address
sensit
technolog
exceed
repetit
sampl
search
space
mandatori
reach
complet
screen
tend
detect
transient
binari
interact
coaffin
purif
coupl
mass
spectrometri
coapm
assay
aim
detect
stabl
complex
explor
overlap
complementari
interact
search
space
figur
one
major
strength
method
compar
perform
morephysiolog
condit
allow
contextdepend
identif
interact
tandem
affin
purif
tap
techniqu
variat
coaffin
purif
character
lower
contamin
background
tap
strategi
involv
use
two
tag
two
sequenti
step
affin
purif
method
use
gener
largest
number
vh
ppi
data
target
host
protein
viral
immun
modul
tumor
viru
protein
identifi
respect
vh
protein
associ
figur
protein
array
technolog
emerg
promis
approach
studi
vh
ppi
figur
first
screen
origin
array
print
human
viral
leucin
zipper
region
human
basic
leucin
zipper
domain
protein
four
viral
protein
probe
fluoresc
label
version
protein
interact
detect
approach
well
valid
circular
dichroism
cd
spectroscopi
determin
whether
chang
conform
protein
interact
use
cd
confirm
retest
interact
second
screen
perform
use
commerci
human
protein
microarray
kit
contain
human
protein
identifi
interact
hcv
core
protein
probe
technolog
rapidli
evolv
improv
sensit
increas
proteom
coverag
allow
develop
labelfre
optic
tool
quantif
associationdissoci
rate
protein
interact
highthroughput
format
recent
ht
vh
ppi
use
protein
complement
assay
implement
jacob
cowork
figur
compar
vh
interactom
explor
protein
rang
pathogen
nonpathogen
human
papillomavirus
benchmark
method
random
protein
pair
posit
refer
set
confirm
perform
assay
highthroughput
set
presenc
fals
posit
fals
neg
inher
ht
qualiti
control
dataset
major
issu
multipl
approach
develop
strategi
includ
diversif
report
gene
low
plasmid
copi
number
retest
hit
subclon
orf
fresh
yeast
greatli
help
improv
qualiti
dataset
databas
cdna
consid
fals
posit
classic
system
also
avail
work
progress
thank
work
golemi
cowork
relat
attempt
last
year
crapom
databas
repositori
common
contamin
coapm
experi
construct
allow
better
character
background
associ
technolog
exampl
protein
bind
bead
matrix
use
precipit
antibodi
conjug
bead
epitop
tag
recent
technic
improv
also
contribut
lower
rate
contamin
one
techniqu
known
stabl
isotop
label
amino
acid
cell
cultur
silac
coupl
coaffin
purif
silac
power
tool
discrimin
background
specif
interact
cell
express
protein
interest
control
cell
label
differ
nonradioact
isotop
heavi
h
light
l
quantif
h
l
ratio
protein
copurifi
bait
protein
allow
rel
quantif
recov
protein
nonspecif
bind
lead
ratio
wherea
high
ratio
indic
possibl
specif
interact
method
success
appli
interactom
map
nucleocapsid
protein
highli
pathogen
north
american
porcin
reproduct
respiratori
syndrom
viru
human
respiratori
syncyti
viru
protein
coronaviru
infecti
bronchiti
nucleocapsid
protein
gag
protein
protein
dengu
viru
type
protein
influenza
viru
approach
complementari
allow
explor
differ
interact
search
space
method
also
develop
amen
highthroughput
format
among
mappit
cytokinebas
mammalian
ppi
trap
assay
lumier
tagprecipit
assay
coupl
renilla
luciferas
knowledg
none
method
yet
appli
highthroughput
vh
ppi
studi
system
biolog
reductionist
approach
complementari
build
comprehens
landscap
viral
infect
replic
highthroughput
screen
reveal
larg
number
vh
ppi
numer
studi
also
provid
detail
often
mechanist
orient
inform
specif
vh
interact
therefor
challeng
identifi
wealth
vh
ppi
data
avail
literatur
sever
databas
develop
captur
structur
data
either
text
mine
manual
curat
intern
molecular
exchang
imex
consortium
consid
key
public
curat
data
focus
manual
curat
data
ensur
highqual
dataset
requir
analysi
creat
intern
collabor
framework
coordin
major
publicinteract
data
provid
share
literatur
curat
workload
appli
highlevel
qualiti
standard
provid
scientif
commun
uniqu
access
data
imex
strategi
limit
redund
well
inconsist
improv
curat
coverag
imex
partner
adopt
common
curat
polici
entail
use
control
vocabulari
format
first
standard
human
proteom
organ
hupo
proteom
standard
initi
molecular
interact
psimi
work
group
vh
ppi
repres
nearli
nonredund
physic
interact
highlight
search
avail
databas
intactmint
dip
uniprot
search
juli
octob
tabl
vh
ppi
also
access
virusmentha
iter
interactom
browser
mentha
present
nonredund
virusrel
interact
extract
manual
curat
ppi
databas
adher
requir
imex
consortium
tabl
final
virhostnet
databas
also
offer
highqual
dataset
approxim
curat
vh
ppi
updat
sinc
tabl
addit
effort
construct
clean
repositori
vh
ppi
made
difficult
trace
often
result
isol
initi
sever
year
perform
manual
curat
vh
ppi
literatur
accord
psimi
standard
experi
highli
demand
task
especi
come
virus
speci
strain
protein
identifi
clearli
defin
matur
protein
often
identifi
viral
polyprotein
sequenc
paper
larg
dataset
also
often
difficult
process
inconveni
format
heterogen
proteinannot
system
number
public
describ
vh
ppi
involv
viral
speci
figur
identif
nonredund
vh
ppi
grow
exponenti
sinc
use
ht
method
figur
accumul
vh
ppi
also
might
allow
increas
confid
interact
redundantli
describ
literatur
despit
effort
gain
confid
ht
data
overlap
vh
ppi
dataset
often
low
experiment
protocol
yet
standard
lab
lab
choic
technolog
differ
score
cutoff
instanc
popular
strategi
far
construct
vh
interactom
technolog
variat
gener
approach
import
differ
essenti
step
report
gene
yeast
strain
plasmid
copi
number
fusion
protein
stringenc
condit
librari
obviou
impact
outcom
experi
anoth
import
consider
dynam
natur
mani
vh
ppi
cours
infect
instanc
sindbi
viru
protein
shown
interact
sever
heterogen
nuclear
ribonucleoprotein
primarili
earli
time
infect
wherea
interact
epsilon
zeta
eta
observ
later
time
infect
sindbi
viru
protein
found
associ
five
specif
host
factor
earli
time
infect
ten
other
later
time
highlight
import
physiolog
context
evolv
infect
also
differ
accord
type
cell
condit
infect
independ
technolog
import
variabl
could
influenc
overlap
vh
screen
heterogen
viru
protein
sequenc
mostli
exemplifi
rna
virus
whose
polymeras
display
high
mutat
rate
consequ
rna
viru
refer
primari
isol
genet
homogen
sequenc
viral
protein
highli
diverg
sequenc
refer
protein
could
respons
loss
gain
interact
final
interact
might
miss
owe
inher
limit
technolog
use
instanc
compat
membran
protein
selfactiv
protein
interact
might
requir
posttransl
modif
mammalian
cell
tag
report
protein
fuse
bait
prey
caus
steric
hindranc
prevent
protein
interact
gain
confid
biophys
interact
orthogon
valid
use
interact
method
therefor
requir
confid
score
calcul
two
decad
studi
vh
ppi
overlap
recent
screen
moststudi
virus
previou
studi
reach
hcv
influenza
viru
protein
bear
consider
mind
possibl
rate
overlap
defin
nearcomplet
dataset
cellular
protein
interact
extens
studi
viru
vh
interactom
repres
interact
might
occur
infect
unambigu
identifi
biolog
relev
cellular
target
function
valid
interact
function
valid
mostli
assess
modul
express
level
cellular
protein
overexpress
knockout
knockdown
recent
explor
hcvhost
ppi
rna
interfer
screen
viral
protein
interactor
reveal
essenti
viral
replic
rate
valid
rang
previou
work
well
rate
identifi
genomewid
small
interf
rna
screen
indic
combin
interactom
function
genom
strongli
enhanc
biolog
relev
cellular
protein
replic
viru
also
consid
instead
modul
quantiti
given
cellular
protein
antivir
molecul
rather
design
inhibit
catalyt
cellular
activ
prevent
viral
protein
interact
one
sever
cellular
partner
therefor
although
combin
highthroughput
strategi
could
help
reduc
number
drugtarget
candid
funnel
effect
drawback
possibl
emerg
falseneg
target
exclus
potenti
interest
drug
candid
highthroughput
screen
studi
vh
interact
initi
implement
provid
comprehens
view
interplay
viru
host
exampl
map
hcv
infect
protein
network
shed
new
light
molecular
basi
coderegul
insulin
jakstat
transform
growth
factor
beta
signal
pathway
involv
frequent
clinic
syndrom
identifi
specif
target
focal
adhes
pathway
thu
provid
new
avenu
studi
tumor
initi
progress
screen
design
identifi
differenti
strategi
exploit
close
relat
virus
perturb
cellular
network
compar
interactom
human
papillomaviru
protein
cluster
protein
accord
pathogen
potenti
viral
strain
highrisk
versu
lowrisk
give
clue
potenti
therapi
target
specif
protein
tap
approach
appli
profil
interactom
viral
immun
modul
viral
speci
identifi
unexpect
varieti
cellular
mechan
exploit
individu
virus
famili
group
simultan
systemat
studi
dna
vh
interactom
includ
papillomaviru
epsteinbarr
viru
adenoviru
polyomaviru
use
screen
tap
tag
purif
transcriptom
network
perturb
reveal
rewir
cellular
network
highlight
notch
signal
pathway
deregul
apoptosi
virusinduc
cancer
first
compar
map
interact
set
influenza
viru
protein
chosen
sequenc
divers
reveal
cellular
target
involv
step
infecti
process
share
major
viral
protein
beyond
establish
vh
interactom
discoveri
specif
common
cellular
function
target
virus
studi
reveal
fundament
principl
evolv
virus
manipul
cellular
network
comput
analysi
networkdescript
metric
degre
between
rais
strike
observ
regard
central
viral
target
context
human
protein
network
inde
viral
protein
show
preferenti
interact
highdegre
cellular
protein
protein
high
number
direct
interact
partner
therefor
local
highli
connect
human
interactom
viral
protein
also
strong
tendenc
interact
cellular
protein
high
between
global
central
measur
number
shortest
path
pass
given
protein
reflect
flux
inform
control
protein
topolog
characterist
cellular
protein
target
viral
protein
observ
unbias
highthroughput
vh
interact
screen
indic
function
import
characterist
anoth
gener
hallmark
virus
compens
small
proteom
abil
interact
numer
cellular
protein
allow
evolv
intrins
disord
protein
region
enrich
short
linear
motif
involv
multipl
interact
human
protein
network
motif
adopt
characterist
host
use
strategi
molecular
mimicri
exampl
pdzbind
motif
carboxyl
terminu
avian
influenza
protein
polyprolin
motif
hcv
protein
abl
interact
srchomolog
domain
cellular
protein
taken
togeth
proteom
analys
boost
knowledg
viral
replic
diseas
etiolog
allow
identif
new
cellular
target
might
suitabl
drug
develop
search
effect
therapeut
treat
viral
infect
activ
area
research
mani
year
result
success
failur
chronic
infect
virus
hiv
hepat
b
viru
hbv
control
requir
lifelong
treatment
treatment
acut
viral
infect
exampl
respiratori
virus
highli
pathogen
emerg
rna
virus
either
poorli
effect
exist
overal
treatment
viral
infect
larg
remain
unmet
medic
need
despit
intens
research
activ
addit
target
viral
compon
directact
drug
tabl
recent
effort
focus
identif
essenti
host
factor
target
new
antivir
target
host
factor
dramat
enlarg
repertoir
therapeut
target
offer
greater
barrier
emerg
resist
target
host
molecul
potenti
broadspectrum
indic
target
pathway
share
differ
variant
given
viru
differ
type
viru
although
far
complet
construct
vh
interactom
start
support
activ
field
identifi
best
cellular
protein
target
antivir
activ
antivir
small
molecul
inhibit
cellular
function
vh
ppi
report
literatur
current
databas
develop
refer
review
select
hostori
molecul
antivir
activ
vitro
vivo
two
major
virus
infect
human
influenza
hcv
antivir
market
worth
us
billion
high
growth
rate
recurr
season
influenza
repres
signific
part
market
world
popul
infect
year
influenza
viru
highli
effect
panstrain
vaccin
remain
major
object
protect
popul
infect
current
protect
reli
annual
vaccin
offer
variabl
unpredict
efficaci
antivir
neuraminidas
inhibitor
oseltamivir
zanamavir
use
treatment
establish
ill
pre
postexposur
prophylaxi
specif
situat
howev
effect
drug
strongli
question
emerg
resist
chang
season
pandem
strain
decreas
drug
respons
limit
therapeut
option
epidem
pandem
influenza
novel
approach
develop
influenza
drug
public
health
prioriti
inhibit
influenza
viru
replic
drug
target
cellular
protein
cellular
function
establish
concept
earli
studi
first
use
drug
basic
research
soon
inhibitor
protein
kinas
c
pkc
rafmekerk
signal
cascad
test
therapeut
potenti
sinc
compound
target
host
protein
identifi
inhibitori
impact
influenza
viru
replic
figur
compound
target
larg
divers
cellular
protein
act
almost
step
viru
replic
cycl
mani
inhibitori
molecul
origin
develop
anticanc
indic
includ
agent
mek
inhibitor
obatoclax
gemcitabin
flavopiridol
anticytoskelet
drug
etoposid
among
other
drug
inher
toxic
test
longterm
treatment
note
treatment
sever
influenza
viru
infect
expect
last
day
treatment
nonsever
influenza
infect
addit
molecul
activ
sought
sever
extend
interactom
identifi
cellular
target
viral
protein
provid
use
lead
mention
major
problem
use
directact
drug
treatment
viral
infect
high
frequenc
emerg
resist
strain
develop
hosttarget
therapi
expect
reduc
risk
test
experiment
repetit
cultur
influenza
viru
pressur
directact
hostori
drug
five
ten
passag
reduct
antivir
effect
observ
use
hostori
molecul
mek
inhibitor
inhibitor
inhibitor
wherea
use
directact
drug
oseltamivir
amantadin
two
class
approv
drug
treatment
influenza
led
rapid
emerg
resist
variant
indic
viru
easili
adapt
situat
cellular
function
essenti
replic
becom
less
access
suggest
target
host
confer
greater
barrier
develop
viral
resist
current
lasag
lysin
acetyl
salicyl
glycin
first
molecul
target
host
intracellular
protein
undergo
phase
ii
clinic
trial
treatment
sever
influenza
viru
infect
inhibitor
expect
limit
product
deleteri
cytokin
infect
highli
pathogen
influenza
virus
virushost
ppi
also
provid
huge
potenti
develop
antivir
molecul
directli
interfer
vh
interact
experiment
molecul
disrupt
vh
ppi
alreadi
investig
variou
virus
sever
pharmaceut
biotechnolog
compani
project
focus
identif
develop
drug
host
target
vh
ppi
tabl
alisporivir
one
advanc
molecul
kind
reach
phase
iii
trial
antihcv
therapi
part
interferonfre
treatment
combin
chronic
hepat
c
genotyp
patient
howev
fda
put
trial
hold
assess
possibl
sideeffect
pancreat
phase
ii
trial
recruit
chronic
hepat
c
genotyp
ongo
drug
nonimmunosuppress
deriv
cyclosporin
csa
precis
mechan
action
hcv
infect
initi
unknown
later
shown
csa
disrupt
interact
cyclophilin
bind
peptidylprolyl
isomeras
hydrophob
pocket
cyclophilin
use
alisporivir
also
provid
high
barrier
emerg
resist
multipl
mutat
domain
ii
requir
vitro
hcv
becom
resist
even
interfer
vh
ppi
small
molecul
prove
effect
specif
antivir
indic
accumul
success
exampl
necessari
approach
widespread
applic
date
molecul
target
intracellular
host
protein
fda
approv
antivir
indic
thu
whether
drug
truli
suitabl
treatment
viral
infect
remain
open
question
mostli
potenti
side
effect
nevertheless
worth
note
convent
antivir
compound
actual
quit
toxic
moreov
durat
treatment
mostli
acut
infect
influenza
virus
expect
exceed
day
could
moder
incid
side
effect
sever
discoveri
new
antivir
acceler
ration
integr
vh
interactom
drugrel
databas
vh
ppi
repertoir
indic
cellular
protein
essenti
replic
given
viru
therefor
cellular
protein
consid
potenti
therapeut
target
whose
function
could
manipul
exist
small
molecul
prevent
viral
usag
interfer
viral
replic
modul
cellular
function
either
approv
govern
author
clinic
develop
indic
could
reposit
new
antivir
agent
databas
collect
inform
bioactiv
small
molecul
protein
target
numer
differ
mainli
focu
detail
level
tabl
first
comparison
resourc
highlight
specif
complementari
howev
standard
term
target
term
chemic
entiti
remain
crucial
challeng
preliminari
attempt
aggreg
sever
druggen
interact
resourc
avail
druggen
interact
databas
dgidb
databas
allow
explor
human
druggabl
genom
combin
evolv
vh
ppi
dataset
drugtarget
interact
describ
drugbank
alreadi
reveal
great
potenti
drug
repurpos
discoveri
antivir
molecul
figur
potenti
acceler
sinc
first
highthroughput
screen
vh
ppi
sinc
highthroughput
technolog
appli
vh
interactom
number
ppi
human
target
grow
exponenti
ever
sinc
overal
new
dataset
pave
way
comprehens
understand
viru
lifecycl
hostcel
respons
also
open
new
horizon
discoveri
hostori
drug
wherea
antivir
molecul
develop
far
target
viral
compon
basic
pharmaceut
research
move
toward
target
host
protein
success
exampl
includ
fdaapprov
maraviroc
treatment
hiv
infect
promis
result
exampl
influenza
lasag
phase
ii
clinic
trial
vectura
chippenham
uk
hepat
c
alisporivir
phase
ii
clinic
trial
novarti
basel
switzerland
pioneer
studi
also
demonstr
reduct
rate
emerg
antivir
resist
explos
number
potenti
target
owe
recent
use
highthroughput
technolog
also
result
explos
number
antivir
drug
candid
use
reposit
strategi
exist
drug
experiment
molecul
virushost
interactom
far
complet
would
greatli
benefit
diversif
proteininteract
detect
method
allow
comprehens
explor
interactom
space
anoth
major
concern
qualiti
complet
human
interactom
import
priorit
target
propos
strategi
drug
combin
base
network
pharmacolog
virus
evolv
host
manipul
numer
cellular
function
much
also
learnt
control
cellular
function
impair
noninfecti
patholog
instanc
bioenerget
metabol
play
pivot
role
replic
virus
target
metabol
viral
protein
translat
clinic
symptom
best
exemplifi
chronic
hepat
c
character
metabol
dysfunct
includ
insulin
resist
interestingli
activ
hexokinas
first
ratelimit
enzym
glycolysi
increas
upon
interact
hcv
protein
mimick
mechan
viral
protein
control
first
step
glycolysi
make
possibl
develop
novel
therapeut
strategi
potenti
glycolysi
metabol
diseas
test
hypothesi
genom
mutat
tumor
virus
might
caus
cancer
relat
mechan
rozenblattrosen
colleagu
show
analysi
cellular
target
tumor
viru
protein
identifi
cancer
gene
good
success
rate
combin
genom
studi
tumor
vh
interactom
could
therefor
becom
instrument
identif
cancerrel
gene
protein
priorit
therapeut
develop
two
exampl
recent
studi
indic
addit
pave
way
hostori
therapeut
treatment
viral
infect
vh
interactom
also
broad
implic
field
noninfecti
diseas
